Log In
Print
BCIQ
Print
Print this Print this
 

ALN-TTR02

  Manage Alerts
Collapse Summary General Information
Company Alnylam Pharmaceuticals Inc.
DescriptionRNAi therapeutic targeting the transthyretin (TTR) gene using second-generation lipid nanoparticle technology
Molecular Target Transthyretin (TTR)
Mechanism of ActionGene silencing
Latest Stage of DevelopmentPhase II
IndicationAmyloidosis
Partner

Sanofi
 Product Details
 Archive Items are loading loading
Get a free BioCentury trial today